Trials / Terminated
TerminatedNCT02914600
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,188 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filgotinib | Tablet administered orally once a day |
| DRUG | Placebo | Tablet administered orally once a day |
Timeline
- Start date
- 2017-03-17
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2016-09-26
- Last updated
- 2024-07-10
- Results posted
- 2024-07-10
Locations
486 sites across 40 countries: United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Georgia, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02914600. Inclusion in this directory is not an endorsement.